SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study
I'm PortAI, I can summarize articles.
SeaStar Medical Holding Corporation has published a health economic study on its QUELIMMUNE therapy for pediatric Acute Kidney Injury (AKI). The study reveals an estimated 18% reduction in hospitalization costs, translating to savings of $69,146 per hospitalization compared to standard treatments. The therapy also boasts a 77% survival rate in treated patients. QUELIMMUNE, approved by the FDA in 2024, is aimed at pediatric patients with AKI due to sepsis. SeaStar is conducting further trials to assess the therapy's safety and efficacy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments